



## **Aastrom Biosciences to Hold Investor Conference Call Tomorrow**

**Ann Arbor, Michigan, May 5, 2005** -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it will host an investor conference call tomorrow, Friday, May 6, 2005 at 11:00 a.m. (ET).

Interested parties should call (785) 832-0326, or toll-free (877) 707-9628, fifteen minutes before the start of the call and identify themselves as registrants of the 'Aastrom Conference Call'. The call will be simulcast on the web at <http://phx.corporate-ir.net/playerlink.zhtml?c=85924&s=wm&e=1054502>, and archived for 90 days at the same site.

### **About Aastrom Biosciences, Inc.**

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's strategic position in the tissue regeneration sector is enabled by its proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells, and the AastromReplicell® System, an industry-unique automated cell production platform used to produce cells for clinical use. TRCs are the core component of the products Aastrom is developing for severe bone fractures, ischemic vascular disease, jaw reconstruction and spine fusion, with Phase I/II level clinical trials active in the U.S. and EU for some of these indications.

**For more information, visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).**

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials, product development objectives, potential product applications, and potential advantages of TRCs or the AastromReplicell® System, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the word "plan," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

### **CONTACTS:**

Kris M. Maly or Becky Anderson  
Investor Relations Department  
Aastrom Biosciences, Inc.  
Phone: (734) 930-5777

Kevin McGrath  
Cameron Associates  
Phone: (212) 245-4577